Vistagen Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $8.73M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2027 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | – | – |
| Q4 FY2026 Ended Mar 31, 2026 | Jun 15, 2026 | After market close | – | – | – |
| Q3 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | – | – | – |
| Q2 FY2026 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | $258.00K | $-0.54 | – |
| Q1 FY2026 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | – | – | – |
| Q4 FY2025 Ended Mar 31, 2025 | Jun 17, 2025 | After market close | – | – | – |
| Q3 FY2025 Ended Dec 31, 2024 | Feb 13, 2025 | After market close | $234.00K | $-0.46 | – |
| Q2 FY2025 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | – | – | – |
| Q1 FY2025 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | $84.00K | $-0.35 | – |
| Q4 FY2024 Ended Mar 31, 2024 | Jun 11, 2024 | After market close | – | – | – |
| Q3 FY2024 Ended Dec 31, 2023 | Feb 13, 2024 | After market close | – | – | – |
Press releases
Announcements Vistagen Therapeutics filed with the SEC
1 Nasdaq: VTGN Corporate Presentation Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry September 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Reports Positive Findings Supporting Fasedienol’s Potential
Other events · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vistagen Team Conference Call Participants Shawn K. Singh, J.D. President and Chief Executive Officer Joshua Prince, MBA Chief Operating Officer Mark A. McPartland Senior Vice President Investor Relations Angel S. Angelov, MD., MBA Chief Medical Officer
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Appoints Nick Tressler as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Appoints Paul Edick to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pherines Harnessing the power and potential of nose-to-brain neurocircuitry
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Results of operations · Other events · EX-99.1 to Form 8-K
Vistagen on Track to Deliver Topline Data from Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of this Year
Regulation FD disclosure · EX-99.1 to Form 8-K
Pherines Harnessing the power and potential of nose-to-brain neurocircuitry
Regulation FD disclosure · EX-99.2 to Form 8-K
Pherines Harnessing the power and potential of nose-to-brain neurocircuitry
Other events · EX-99.1 to Form 8-K
Vistagen to Participate in Stifel 2025 Virtual CNS Forum
Other events · EX-99.2 to Form 8-K
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Pherines A new medication class harnessing the therapeutic potential of nose-to-brain neurocircuitry
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
Other events · EX-99.1 to Form 8-K
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
Other events · EX-99.1 to Form 8-K
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Other events · EX-99.1 to Form 8-K
Acute Treatment of Social Anxiety Disorder Fasedienol
Regulation FD disclosure · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Other events · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
Other events · EX-99.1 to Form 8-K
Vistagen Awarded Mental Health America ’ s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Other events · EX-99.1 to Form 8-K
Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K